BUZZ - Align Technology shares fall as annual revenue forecast misses expectations
路透社2026/10/28 21:06October 28 - ** Align Technology (ALGN.O) shares fell 1.4% in after-hours trading to $151.45
** According to data compiled by London Stock Exchange Group (LSEG), the dental aligner manufacturer expects 2026 revenue to be between $4.11 billion and $4.13 billion, while analysts had expected $4.15 billion
** Fourth-quarter revenue is expected to be between $1 billion and $1.02 billion, compared with analysts’ estimate of $1.048 billion
** ALGN reported adjusted third-quarter earnings per share of $2.80, while analysts had expected $2.78
** The report shows third-quarter revenue of $1.015 billion, compared with the market expectation of $1.005 billion
** The company appointed former Procter & Gamble global health care business CEO Jennifer Davis as its next President and Chief Executive Officer, effective December 31
** Davis will succeed Joseph Hogan, who has led the company since 2015
** As of the last close, the stock is down 1.6% year-to-date
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may contain errors or lack the desired context, and Reuters does not guarantee the accuracy of the automated translation. This service is provided solely for readers’ convenience. Reuters accepts no responsibility for any harm or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
